罗哌卡因用于连续臂丛神经阻滞的最低运动阻滞浓度分析

发布时间：2018-05-13 20:35

本文选题：罗哌卡因 + 臂丛　；参考：《重庆医学》2017年29期

【摘要】：目的确定罗哌卡因用于连续臂丛神经阻滞的最低运动阻滞浓度(MMLAC),使患者获得无痛状态下的早期自主功能锻炼。方法选取2014年6月至2016年9月创伤后在该院行肘关节松解手术的患者60例,术中在B型超声引导下行锁骨下入路置管,术后以罗哌卡因配伍罂粟碱进行术后止痛。采用上下序贯法,罗哌卡因起始浓度0.200%,间隔浓度0.005%,通过概率单位回归分析法计算MMLAC。结果采用概率单位回归分析法得出罗哌卡因用于连续臂丛神经阻滞的MMLAC,即运动阻滞的半数有效浓度(EC50)为0.191%,其95%CI为0.189%~0.192%。结论盐酸罗哌卡因配伍罂粟碱应用于锁骨下入路臂丛神经运动阻滞的MMLAC为0.191%,在此浓度下患者可以达到最舒适、早期无痛自主的功能锻炼。
[Abstract]:Objective to determine the minimum motor block concentration of ropivacaine for continuous brachial plexus block and to obtain early autonomic exercise in painless state. Methods from June 2014 to September 2016, 60 patients undergoing elbow joint release were treated with B-mode ultrasound guided subclavian approach. Ropivacaine combined with papaverine was used to relieve pain after operation. The MMLAC was calculated by the method of sequential up and down, the initial concentration of ropivacaine was 0.200 and the interval concentration was 0.005. The MMLACwas calculated by the method of probability unit regression analysis. Results by using the probabilistic unit regression analysis, the MMLAC of ropivacaine for continuous brachial plexus block (EC50) was 0.191, and its 95%CI was 0.189g / 0.1922. Conclusion the MMLAC of ropivacaine hydrochloride combined with papaverine in subclavian brachial plexus motor block is 0.191. At this concentration, patients can achieve the most comfortable, painless and autonomous early functional exercise.
【作者单位】：贵州省贵阳市第四人民医院麻醉科;
【基金】：贵州省贵阳市科技计划基金资助项目[筑科合同(20151001)社4号] 贵州省贵阳市卫生和计划生育委员会科学技术计划基金资助项目[(2015)筑科卫计科技合同第048号]
【分类号】：R614

【相似文献】